Delcath's Q2 Preview: Can One More Good Quarter Keep the $100M Story Alive?

Q2 has to validate whether Delcath's scale story is repeatable

Delcath's Aug. 6 after-hours earnings report matters because investors need one more quarter of evidence that growth is carrying into 2026, not fading after a strong start. The stock is trading around $10.78 in extended trading, and with Q2 consensus EPS at -$0.09, the market is not demanding full profitability. It is demanding another quarter that keeps the revenue arc credible after Q1 revenue of $25.0 million.

What investors need from the quarter

Q1 showed the commercial engine is real. HEPZATO KIT drove most of the top line, while CHEMOSAT remained a smaller but strategically important second lane after earning ESMO–EURACAN guideline inclusion. Gross margin also held at 85%, suggesting the business can grow without immediately losing its margin profile.

The key question is whether that first-quarter momentum looks sustainable. Another solid quarter would support management's 2026 guidance of at least $100 million in revenue. A merely decent quarter would leave investors focused on whether the growth burst was temporary.

Revenue follow-through matters more than a simple beat or miss

What investors need is not just another acceptable quarter. They need signs that Delcath is converting demand into a repeatable operating pattern: procedure volume keeps rising, center activity broadens, and reimbursement continues to support the workflow. If those pieces are moving together, the story shifts from one good quarter to a credible annual run rate.

HEPZATO is still doing the heavy lifting

In Q1, HEPZATO KIT revenue of $23.3 million accounted for most total revenue, while CHEMOSAT revenue of $1.7 million remained small but notable. Bulls will point to the roughly 36% growth in HEPZATO volume as evidence that uptake is real. Skeptics will ask whether that growth came from more regular use across existing centers, more cases per center, or expansion into new treatment patterns.

Delcath's recent earnings record also argues against treating one headline number as the whole story. In Q1 2025, it missed EPS expectations with $0.03 versus $0.10 consensus even as revenue came in above expectations at $19.80 million versus $16.83 million. At the same time, the company has surpassed consensus EPS estimates three times in the last four quarters. For this report, that means commentary on demand, center activity, and repeat use may matter as much as the beat-or-miss headline.

Center activity and reimbursement are the real check

The company reported 29 active centers in Q1. Investors should listen for evidence that those centers are doing more with the product, that new centers are converting into repeat demand, and that reimbursement is supporting the workflow instead of slowing it.

That is why the April guideline win matters, but only up to a point. CHEMOSAT's ESMO–EURACAN guideline inclusion strengthens the longer-term case, yet guidelines alone do not create near-term revenue. The same press release also noted HEPZATO KIT as a Category 2A recommended treatment option, which helps the broader adoption story if it translates into more procedures.

Cash flow is a watchpoint, not a automatic disqualifier

The first-quarter cash picture also deserves attention. Cash provided by operations of $0.9 million was below $2.2 million in the first quarter of 2025, and non-GAAP adjusted EBITDA fell to $3.4 million from $7.6 million a year earlier. Bulls can argue that a growing build phase can look messy in the short term. Skeptics will say operating leverage needs to improve alongside revenue.

Three signals that likely decide the stock's next move

At the print, the main question is whether Q1 revenue of $25.0 million is becoming a repeatable quarterly run rate. Four quarters at that level would equal Delcath's 2026 guidance of at least $100 million. With Q2 consensus EPS at -$0.09, investors are mainly looking for proof that the commercial engine is still building rather than peaking.

Signal 1: Revenue needs to look like a base, not a burst

Confirmation: - Q2 revenue lands near the roughly $25.0 million Q1 run rate. - HEPZATO KIT continues to drive the majority of revenue, with HEPZATO KIT revenue of $23.3 million setting the benchmark. - Management describes growth spreading across the 29 active centers rather than relying on a one-time surge.

Invalidation cue: - Revenue comes in materially below that run rate. - Guidance language gets less confident without a clearer story on center activity and repeat procedures.

Signal 2: The earnings trade-off has to sound deliberate

Confirmation: - Management frames a weaker earnings quarter as spending tied to scaling the business, not as demand rolling over. - The company can still point to a track record of execution, including surpassing consensus EPS estimates three times in the last four quarters.

Invalidation cue: - The loss widens more than expected because of expense burn rather than disciplined investment. - Commentary makes non-GAAP adjusted EBITDA of $3.4 million and cash provided by operations of $0.9 million look like signs of weak operating leverage instead of a temporary build phase.

Signal 3: CHEMOSAT has to look like a future second lane

Confirmation: - Management connects the ESMO–EURACAN guideline inclusion to practical adoption steps, not just prestige. - CHEMOSAT is discussed as a companion growth lane that can broaden the business beyond the current core.

Invalidation cue: - Leadership spends most of the call on long-term vision while avoiding near-term questions on volume, center expansion, and repeat use. - Investors leave thinking the story still depends mainly on HEPZATO for now, with CHEMOSAT still more narrative than revenue contribution.